Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., known for its advanced drug delivery technology, is set to present promising initial results from a Phase 1b study of EP-104GI in treating eosinophilic esophagitis at the Digestive Disease Week 2024. The company successfully completed a Phase 2b trial for osteoarthritis knee pain, and it’s expanding its EP-104 platform to gastrointestinal diseases, signifying progress in its diverse clinical pipeline. The presentation by Chief Scientific Officer, Dr. Amanda Malone, will happen in Washington, D.C., highlighting Eupraxia’s commitment to addressing unmet medical needs with its DiffuSphere™ technology.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
